NWBO
Northwest Biotherapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Dec. 8, 3:23 PM
    • Citing its lack of progress in convincing regulators to lift the suspension on recruiting patients and the effort involved in retraining and restarting trial sites, Northwest Biotherapeutics (NWBO +0.1%) settles on total enrollment of 331 in its Phase 3 study of DCVax for the treatment of glioblastoma multiforme (brain cancer), 17 short of its target of 348.
    • Investigators have been unable to recruit additional subjects after a partial clinical hold was put into place in August 2015. A partial clinical hold suspends new recruitment but allows patients who are already enrolled to continue receiving the study drug.
    • The company believes that the current enrollment of 331 will be sufficient to amass the necessary number of events to achieve statistically valid results.
    | Thu, Dec. 8, 3:23 PM | 12 Comments
  • Wed, Dec. 7, 10:43 PM
    • Saying Nasdaq has not accepted it plan to fix its listing deficiencies, Northwest Biotherapeutics (NASDAQ:NWBO) will voluntarily withdraw its listing on or about December 19. It will trade on the over-the-counter (OTC) market thereafter, specifically the OTCQB Venture Market (if its application is accepted).
    • The company says the move will enhance its ability to raise funds since it will not be subject to the same "restrictions."
    | Wed, Dec. 7, 10:43 PM | 7 Comments
  • Thu, Nov. 17, 9:41 AM
    • Northwest Biotherapeutics (NWBO +12.8%) teams up with the University Medical Center of the Johannes Gutenbury University Mainz in Germany in a Phase 2 clinical trial assessing the combination of DCVax-L and Merck's (MRK -0.4%) PD-1 inhibitor Keytruda (pembrolizumab) in patients with colorectal cancer with liver metastases.
    • After receiving the necessary regulatory approvals, the study will treat patients for up to six months with the combination followed by a long-term follow-up period to assess survival.
    | Thu, Nov. 17, 9:41 AM | 22 Comments
  • Fri, Oct. 21, 10:37 AM
    • Nano cap Northwest Biotherapeutics (NWBO -17.3%) slumps on increased volume in response to its announcement that it has inked a deal with an institutional investor for the direct placement of up to 14M shares of common stock at $0.38, almost a 30% discount to yesterday's close of $0.5384. Closing date is October 26.
    • Shares have lost over 96% of their value since July 2015.
    | Fri, Oct. 21, 10:37 AM | 23 Comments
  • Tue, Sep. 13, 1:12 PM
    • Nano cap Northwest Biotherapeutics (NWBO +49.8%) shows some oomph today on more than a 13x surge in volume. No particular news accounts for the unusual action, especially considering the market's down day.
    • A week ago, Nasdaq informed the company that its remediation plan to address its failure to comply with listing rules regarding its unregistered issuance of securities to Cognate BioServices was acceptable and the company had regained compliance with rules. In other words, the matter has been closed.
    • During the DCVax-L Phase 3 study in GBM brain cancer, NWBO paid some of Cognate's invoices in restricted stock instead of cash. The shares were unregistered despite contractual obligations to register them.
    | Tue, Sep. 13, 1:12 PM | 25 Comments
  • Tue, Aug. 23, 10:19 AM
    • Northwest Biotherapeutics (NWBO -9.2%) eases on average volume in response to its disclosure that it discounted the exercise prices for certain warrant holders as an inducement to raise ~$1.3M in new capital. The company offered an exercise price of $0.35 a share for warrants to purchase up to 3,656,817 shares of common stock with original exercise prices of $4.50 - 6.00.
    • In addition, Northwest issued new five-year Series E Warrants to the same warrant holders to purchase up to 3,656,817 shares of common stock at $0.41 a share.
    • Net proceeds will fund the start of Phase 2 clinical trials and working capital.
    • Yesterday's close was $0.4077.
    | Tue, Aug. 23, 10:19 AM | 12 Comments
  • Tue, Jul. 5, 10:11 AM
    • Nano cap Northwest Biotherapeutics (NWBO -16.6%) enters into agreements with two institutional investors for the direct placement of 7.4M shares of common stock at $0.50 a share plus five-year warrants to purchase up to 3.7M shares of common at $0.60.
    • The deal should close today.
    | Tue, Jul. 5, 10:11 AM | 10 Comments
  • Mon, May 16, 1:12 PM
    • In a regulatory filing, Northwest Biotherapeutics (NWBO -9.2%) discloses that it lowered the exercise price for holders of certain warrants associated with its recent capital raise. The ~$28M direct offering to institutional investors included Series A warrants to purchase up to 2,205,882 shares of common stock at $2.25, Series B warrants, as an over-allotment option, to purchase up to 4,411,764 shares of common at $3 and Series C warrants which would vest and become exercisable at $4 only if the Series B warrants were fully exercised.
    • On May 15, the company inked a deal with a holder of the Series A, B and C warrants under which the investor agreed to exercise all of the Series B warrants (appears to be the placement agent H.C. Wainwright) but at a discounted exercise price of $0.96, triggering the vesting of the Series C warrants, at a discounted exercise price of $1. The Series C was sold in a concurrent private placement with investors on March 3.
    • Northwest then agreed to issue new Series D warrants to purchase up to 2,205,882 shares of common stock at $1 per share.
    • Shares are currently down 9% but could fall further once investors realize what's happened here.
    • Previously: Northwest Bio executes direct equity offering valued as high as $27.6M; shares off 15% on discount (Feb. 29)
    | Mon, May 16, 1:12 PM | 7 Comments
  • Mon, May 9, 12:50 PM
    | Mon, May 9, 12:50 PM | 1 Comment
  • Thu, Apr. 7, 9:14 AM
    | Thu, Apr. 7, 9:14 AM | 8 Comments
  • Mon, Feb. 29, 12:55 PM
    | Mon, Feb. 29, 12:55 PM
  • Mon, Feb. 29, 12:36 PM
    • Micro cap Northwest Biotherapeutics (NWBO -14.8%) slumps on increased volume in response to its announcement of a direct offering of stock and warrants to institutional investors. The deal consists of 5.88M shares of common stock at $1.70 per share and five-year warrants to purchase up to 2.94M shares of common at $2.25. Gross proceeds will be ~$10M.
    • Investors also have a 60-day over-allotment option to buy up to an additional 5.88M common shares at $3.00 that will include five-year warrants to buy up to 2.94M shares of common at $4.00. Gross proceeds, if fully exercised, will be ~$17.6M.
    • NWBO closed Friday at $2.10.
    | Mon, Feb. 29, 12:36 PM | 7 Comments
  • Mon, Jan. 25, 10:37 AM
    • As part of its effort to give its corporate governance image a facelift in light of allegations of dubious financial dealings by CEO Linda Powers, Northwest Biotherapeutics (NWBO -1.9%) appoints two independent directors, Susan Bayh and Ambassador Cofer Black.
    • Ms. Bayh has over 25 years of industry experience, including board seats on eight public biotechs and multiple leadership positions in three other organizations, including in-house counsel at a major pharma company.
    • Ambassador Black served in the CIA for 28 years including a stint as Director of the Counterterrorist Center. He is currently VP for Global Operations at Raytheon Blackbird, advising the U.S. Government on security and equipment.
    • Previously: Northwest Bio forms Special Committee to investigate alleged questionable financial dealings by CEO Powers (Dec. 8, 2015)
    | Mon, Jan. 25, 10:37 AM | 8 Comments
  • Fri, Jan. 8, 9:32 AM
    | Fri, Jan. 8, 9:32 AM | 36 Comments
  • Thu, Jan. 7, 12:41 PM
    | Thu, Jan. 7, 12:41 PM | 1 Comment
  • Dec. 23, 2015, 12:46 PM
    | Dec. 23, 2015, 12:46 PM | 10 Comments